Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
151 hedge funds and large institutions have $1B invested in Acorda Therapeutics in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 74 increasing their positions, 31 reducing their positions, and 43 closing their positions.
139% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 31
1% less capital invested
Capital invested by funds: $1.01B → $1B (-$5.99M)
15% less funds holding
Funds holding: 178 → 151 (-27)
60% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 43
67% less call options, than puts
Call options by funds: $6.08M | Put options by funds: $18.3M
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$42.7M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$27.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.1M |
| 4 |
HEC
Hudson Executive Capital
New York
|
+$12.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$10.1M |
Top Sellers
ACOR Hedge Fund Activity: Q2 2017 in Review
151 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2017, worth a combined $1B — down 0.59% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of ACOR and 17 opened new positions — a net loss of 26 holders — while 31 trimmed existing stakes and 74 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $42.7M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $69.3M sold.
- 151 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2017, down from 178 in Q1 2017.
- Funds reported $1B of Acorda Therapeutics stock for Q2 2017, down 0.59% quarter-over-quarter.
- 17 funds opened new Acorda Therapeutics positions in Q2 2017 and 43 closed out, a net change of -26 holders.
- The largest Acorda Therapeutics buyer in Q2 2017 was PFM Health Sciences, an estimated $42.7M added.
- The largest Acorda Therapeutics seller in Q2 2017 was Baker Bros. Advisors, an estimated $69.3M sold.
Based on aggregated 13F filings for Q2 2017.